Report Categories
View AllRecent Articles
View All
Illumina Inc ILMN Posts Robust Q1 2026 Earnings Beat Driven by Clinical Sequencing Strength and Surging NovaSeq X Demand
APLM Apollomics highlights oncology pipeline progress and upcoming clinical trial milestones in its latest quarterly earnings report
DNLI Denali reports narrower than expected Q4 2025 per share loss stock rises 065 percent today
TILE Interface delivers 191 percent Q4 2025 EPS beat even as shares dip 018 percent lower today